HSP70-FTO轴在非酒精性脂肪性肝病中的作用及机制研究
批准号:
81870596
项目类别:
面上项目
资助金额:
57.0 万元
负责人:
彭永德
依托单位:
学科分类:
H0707.糖稳态失衡与靶器官胰岛素抵抗
结题年份:
2022
批准年份:
2018
项目状态:
已结题
项目参与者:
范能光、方芳、王雪姣、魏小辉、黄婧婧
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
非酒精性脂肪性肝病(NAFLD)是最常见的肝脏疾病。三酰甘油沉积是NAFLD病理基础,但分子机制尚不明确。课题组前期研究发现,在高脂喂养肥胖小鼠的肝脏及棕榈酸诱导的HepG2肝细胞中热休克蛋白70(HSP70)和肥胖相关基因(FTO)表达均显著上调。利用HSP70shRNA下调肥胖小鼠肝脏HSP70能显著改善肝脏脂质沉积。共聚焦等实验提示HSP70参与FTO核内转移,而FTO促进肝细胞脂质合成。基于上述结果,我们提出HSP70可能通过FTO参与NAFLD的发生。为证明该假说,本课题通过病毒载体在体内外过表达或沉默HSP70或FTO,观察两者对肝脂质沉积的影响。再利用HSP70过表达和FTO干扰验证HSP70通过FTO参与肝脂质沉积;最后,用GST-pull down、Co-IP等技术证实HSP70与FTO相互作用。本课题将揭示HSP70在NAFLD发病中的作用和机制,为其治疗提供新靶点。
英文摘要
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing year by year and showing younger-age trend, has become the most common liver disease.The accumulation of fatty acids and triacylglycerols in the liver is the prerequisite and basis for the occurrence of NAFLD, but the specific molecular mechanism is still unclear.Our previous study found that HSP70 and FTO were up-regulated in high fat-induced mouse liver tissue and palmitate-induced steatosis model.In vitro confocal experiments revealed that HSP70 promoted FTO nuclear transfer as molecular chaperones on high fat. Further studies showed that down-regulation of hepatic HSP70 expression by HSP70 shRNA-related adenovirus can significantly improve the degree of hepatic steatosis. In addition, vitro studies found that FTO promoted lipid synthesis of HepG2 hepatocytes.Based on the above findings,we hypothesize that HSP70 may be involved in the pathogenesis of NAFLD through FTO.In order to prove this hypothesis, we overexpress and silence HSP70 or FTO in hepatocytes respectively by lentivirus and adeno-associated virus in vitro or in vivo to observe their effects on liver lipid synthesis and accumulation. Furthermore, HSP70 gene overexpression and FTO gene interference were used to further confirm whether HSP70 is involved in the pathogenesis of NAFLD through FTO. Finally, we study the interaction between HSP70 and FTO through confocal microscopy, Co-IP and GST-pull down techniques ,and reveal the role of HSP70 in the pathogenesis of NAFLD and provide new ideas and targets for clinical treatment of NAFLD.
非酒精性脂肪性肝病(NAFLD)是目前最常见的肝脏疾病,但其发生机制尚不清楚。本课题的旨在探讨HSP70-FTO轴在NAFLD中的作用和机制。在研究中我们发现:1)HSP70促进肝内脂质沉积:HSP70在体内外NAFLD模型中表达升高,过表达HSP70促进肝内脂质沉积,而沉默HSP70抑制脂质沉积;2)HSP70与FTO关系:HSP70与FTO之间相互作用,抑制FTO的泛素化及其降解,并促进FTO的核转移;3)FTO促进肝内脂质沉积:FTO在体内外NAFLD模型中表达升高,过表达FTO促进肝内脂质沉积,而沉默FTO抑制脂质沉积;4)FTO通过抑制PPARα发挥作用:FTO抑制PPARα表达,激活后者可逆转FTO促进肝细胞脂质沉积作用;5)TRIM21是FTO上游的泛素酶:TRIM21与FTO存在直接相互作用,促进FTO的泛素化;6)TRIM21抑制肝内脂质沉积:TRIM21在NAFLD模型中表达降低,过表达TRIM21抑制肝内脂质沉积。综上所述,HSP70-FTO促进肝内脂质沉积,而FTO的泛素化酶TRIM21抑制肝内脂质沉积及NAFLD的发生。本研究进一步阐明了NAFLD的发生机制,为其治疗提供潜在的治疗靶点。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Association between Chinese visceral adiposity index and metabolic-associated fatty liver disease in Chinese adults with type 2 diabetes mellitus.
中国成人2型糖尿病患者内脏脂肪指数与代谢相关脂肪肝的相关性
DOI:10.3389/fendo.2022.935980
发表时间:2022
期刊:Frontiers in endocrinology
影响因子:5.2
作者:
通讯作者:
Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes.
2型糖尿病患者使用利拉鲁肽与肝纤维化的关系
DOI:10.3389/fendo.2022.935180
发表时间:2022
期刊:Frontiers in endocrinology
影响因子:5.2
作者:
通讯作者:
High Serum FABP4 Levels are Negatively Associated with the Reversion from Prediabetes to Normal Glucose Tolerance: A 2-Year Retrospective Cohort Community Study.
高血清 FABP4 水平与从糖尿病前期恢复到正常糖耐量呈负相关:一项为期 2 年的回顾性队列社区研究
DOI:10.2147/dmso.s374912
发表时间:2022
期刊:Diabetes, metabolic syndrome and obesity : targets and therapy
影响因子:--
作者:
通讯作者:
Analysis of N6-Methyladenosine Methylation Modification in Fructose-Induced Non-Alcoholic Fatty Liver Disease.
果糖诱导的非酒精性脂肪肝中 N6-甲基腺苷甲基化修饰分析
DOI:10.3389/fendo.2021.780617
发表时间:2021
期刊:Frontiers in endocrinology
影响因子:5.2
作者:Luo Y;Zhang Z;Xiang L;Zhou B;Wang X;Lin Y;Ding X;Liu F;Lu Y;Peng Y
通讯作者:Peng Y
Association Between High-Sensitivity C-Reactive Protein and Diabetic Kidney Disease in Patients With Type 2 Diabetes Mellitus.
2 型糖尿病患者高敏 C 反应蛋白与糖尿病肾病之间的关联
DOI:10.3389/fendo.2022.885516
发表时间:2022
期刊:FRONTIERS IN ENDOCRINOLOGY
影响因子:5.2
作者:Tang, Min;Cao, Han;Wei, Xiao-Hui;Zhen, Qin;Liu, Fang;Wang, Yu-Fan;Fan, Neng-Guang;Peng, Yong-De
通讯作者:Peng, Yong-De
细胞骨架蛋白Leupaxin通过糖异生在葡萄糖稳态中的作用及机制研究
- 批准号:--
- 项目类别:面上项目
- 资助金额:53万元
- 批准年份:2021
- 负责人:彭永德
- 依托单位:
Fstl1在胰岛素抵抗中的作用及其机制研究
- 批准号:81370904
- 项目类别:面上项目
- 资助金额:61.0万元
- 批准年份:2013
- 负责人:彭永德
- 依托单位:
内质网应激和炎症因子相互作用与肥胖和胰岛素抵抗关系的研究
- 批准号:81070682
- 项目类别:面上项目
- 资助金额:31.0万元
- 批准年份:2010
- 负责人:彭永德
- 依托单位:
国内基金
海外基金















{{item.name}}会员


